Joint First Quarter 2025 Earnings: EPS Beats Expectations

Simply Wall St

May 10, 2025

Joint (NASDAQ:JYNT) First Quarter 2025 Results

Key Financial Results

Revenue: US$13.1m (down 56% from 1Q 2024).
Net loss: US$506.0k (down by 153% from US$947.0k profit in 1Q 2024).
US$0.033 loss per share (down from US$0.064 profit in 1Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

earnings-and-revenue-history — NasdaqCM:JYNT Earnings and Revenue History May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Joint EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 4.8% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Joint's balance sheet health.

If you're looking to trade Joint, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.